Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the american heart association

Circulation

Volumn 123, Issue 16, 2011, Pages 1788-1830

  Jaff, Michael R ^a   McMurtry, M Sean ^a   Archer, Stephen L ^a   Cushman, Mary ^a   Goldenberg, Neil ^a   Goldhaber, Samuel Z ^a   Jenkins, J Stephen ^a   Kline, Jeffrey A ^a   Michaels, Andrew D ^a   Thistlethwaite, Patricia ^a   Vedantham, Suresh ^a   White, R James ^a   Zierler, Brenda K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ARGATROBAN; BRAIN NATRIURETIC PEPTIDE; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TROPONIN; UROKINASE;

ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD CLOT LYSIS; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENDARTERECTOMY; FIBRINOLYSIS; HEART RIGHT VENTRICLE FUNCTION; HUMAN; INFERIOR CAVA VEIN OBSTRUCTION; LEG THROMBOSIS; LUNG EMBOLISM; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; STENT; SURGICAL THROMBECTOMY;

AMERICAN HEART ASSOCIATION; ANTICOAGULANTS; CARDIOLOGY; FEMORAL VEIN; HUMANS; HYPERTENSION, PULMONARY; ILIAC VEIN; PULMONARY EMBOLISM; THROMBOLYTIC THERAPY; UNITED STATES; VENOUS THROMBOSIS;

EID: 79955555188     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e318214914f     Document Type: Article

References (464)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2010 update: a report from the American Heart Association [published correction appears in Circulation. 2010;121:e260]. Circulation. 2010;121: e46-e215.
2. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276-2315.
3. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [published correction appears in Chest. 2008;134:892]. Chest. 2008;133(suppl): 454S-545S. (Pubitemid 351892971)
4. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389. (Pubitemid 29192409)
5. Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, Conti A, Agnelli G, Berni G. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000;101: 2817-2822. (Pubitemid 30396012)
6. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med. 2002;347:1131-1132.
7. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172: 1041-1046. (Pubitemid 41476544)
8. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2:681-684.
9. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006;113:577-582.
10. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, Rauber K, Iversen S, Redecker M, Kienast J. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997;30: 1165-1171.
11. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 2000;84:548-552.
12. Nendaz MR, Bandelier P, Aujesky D, Cornuz J, Roy PM, Bounameaux H, Perrier A. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost. 2004;91:1232-1236. (Pubitemid 38821282)
13. Uresandi F, Otero R, Cayuela A, Cabezudo MA, Jiménez D, Laserna E, Conget F, Oribe M, Nauffal D. A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism [in Spanish]. Arch Bronconeumol. 2007;43:617-622.
14. Jiménez D, Yusen RD, Otero R, Uresandi F, Nauffal D, Laserna E, Conget F, Oribe M, Cabezudo MA, D?́az G. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest. 2007;132:24-30.
15. Donzé J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, Cornuz J, Meyer G, Perrier A, Righini M, Aujesky D. Prospective validation of the Pulmonary Embolism Severity Index: a clinical prognostic model for pulmonary embolism. Thromb Haemost. 2008;100:943-948.
16. Choi WH, Kwon SU, Jwa YJ, Kim JA, Choi YH, Chang JH, Jung H, Doh JH, Namgung J, Lee SY, Lee WR. The pulmonary embolism severity index in predicting the prognosis of patients with pulmonary embolism. Korean J Intern Med. 2009;24:123-127.
17. Ru?́z-Giménez N, Suárez C, González R, Nieto JA, Todol?́ JA, Samperiz AL, Monreal M; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism: findings from the RIETE Registry. Thromb Haemost. 2008;100:26-31. (Pubitemid 351952971)
18. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134: 479-487. (Pubitemid 27431254)
19. Vieillard-Baron A, Page B, Augarde R, Prin S, Qanadli S, Beauchet A, Dubourg O, Jardin F. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med. 2001;27:1481-1486. (Pubitemid 32835316)
20. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med. 2005;165:1777-1781. (Pubitemid 41138967)
21. Jiang LB, Ying KJ. The impact of right ventricular dysfunction on the clinical outcome of normotensive patients with pulmonary embolism [in Chinese]. Zhonghua Nei Ke Za Zhi. 2007;46:111-113.
22. Frémont B, Pacouret G, Jacobi D, Puglisi R, Charbonnier B, de Labriolle A. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in patients with acute pulmonary embolism: results from a monocenter registry of 1,416 patients. Chest. 2008;133:358-362. (Pubitemid 351272392)
23. Kjaergaard J, Schaadt BK, Lund JO, Hassager C. Prognostic importance of quantitative echocardiographic evaluation in patients suspected of first non-massive pulmonary embolism. Eur J Echocardiogr. 2009;10: 89-95.
24. Araoz PA, Gotway MB, Trowbridge RL, Bailey RA, Auerbach AD, Reddy GP, Dawn SK, Webb WR, Higgins CB. Helical CT pulmonary angiography predictors of in-hospital morbidity and mortality in patients with acute pulmonary embolism. J Thorac Imaging. 2003;18:207-216. (Pubitemid 37310723)
25. Quiroz R, Kucher N, Schoepf UJ, Kipfmueller F, Solomon SD, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation. 2004;109:2401-2404. (Pubitemid 38679558)
26. Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 2004;110:3276-3280. (Pubitemid 39525077)
27. Ghuysen A, Ghaye B, Willems V, Lambermont B, Gerard P, Dondelinger RF, DOrio V. Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism. Thorax. 2005;60:956-961. (Pubitemid 41598212)
28. van der Meer RW, Pattynama PM, van Strijen MJ, van den Berg- Huijsmans AA, Hartmann IJ, Putter H, de Roos A, Huisman MV. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology. 2005;235:798-803. (Pubitemid 40695872)
29. Araoz PA, Gotway MB, Harrington JR, Harmsen WS, Mandrekar JN. Pulmonary embolism: prognostic CT findings. Radiology. 2007;242: 889-897.
30. Subramaniam RM, Mandrekar J, Chang C, Blair D, Gilbert K, Peller PJ, Sleigh J, Karalus N. Pulmonary embolism outcome: a prospective evaluation of CT pulmonary angiographic clot burden score and ECG score. AJR Am J Roentgenol. 2008;190:1599-1604. (Pubitemid 351798522)
31. Findik S, Erkan L, Light RW, Uzun O, Atici AG, Akan H. Massive pulmonary emboli and CT pulmonary angiography. Respiration. 2008; 76:403-412.
32. Stein PD, Beemath A, Matta F, Goodman LR, Weg JG, Hales CA, Hull RD, Leeper KV Jr, Sostman HD, Woodard PK. Enlarged right ventricle without shock in acute pulmonary embolism: prognosis. Am J Med. 2008;121:34-42.
33. Nural MS, Elmali M, Findik S, Yapici O, Uzun O, Sunter AT, Erkan L. Computed tomographic pulmonary angiography in the assessment of severity of acute pulmonary embolism and right ventricular dysfunction. Acta Radiol. 2009;50:629-637.
34. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 2003;107: 2545-2547. (Pubitemid 36628932)
35. ten Wolde M, Tulevski II, Mulder JW, Sohne M, Boomsma F, Mulder BJ, Büller HR. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation. 2003;107: 2082-2084.
36. Krüger S, Graf J, Merx MW, Koch KC, Kunz D, Hanrath P, Janssens U. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J. 2004;147:60-65. (Pubitemid 38037398)
37. Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, Grifoni S, Berni G. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol. 2006;97: 1386-1390.
38. Ray P, Maziere F, Medimagh S, Lefort Y, Arthaud M, Duguet A, Teixeira A, Riou B. Evaluation of B-type natriuretic peptide to predict complicated pulmonary embolism in patients aged 65 years and older: brief report. Am J Emerg Med. 2006;24:603-607. (Pubitemid 44308385)
39. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation. 2003;107:1576-1578. (Pubitemid 36397323)
40. Pruszczyk P, Kostrubiec M, Bochowicz A, Styczyński G, Szulc M, Kurzyna M, Fijalkowska A, Kuch-Wocial A, Chlewicka I, Torbicki A. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J. 2003;22:649-653. (Pubitemid 37258545)
41. Kostrubiec M, Pruszczyk P, Kaczynska A, Kucher N. Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. Clin Chim Acta. 2007;382:124-128. (Pubitemid 46782748)
42. Alonso-Mart?́nez JL, Urbieta-Echezarreta M, Anniccherico- Sánchez FJ, Ab?́nzano-Guillén ML, Garcia-Sanchotena JL. N-terminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism. Am J Med Sci. 2009;337:88-92.
43. Giannitsis E, Müller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M, Katus HA. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation. 2000;102:211-217. (Pubitemid 30451779)
44. Janata K, Holzer M, Laggner AN, Müllner M. Cardiac troponin T in the severity assessment of patients with pulmonary embolism: cohort study. BMJ. 2003;326:312-313. (Pubitemid 36205164)
45. Bova C, Crocco F, Ricchio R, Serafini O, Greco F, Noto A. Importance of troponin T for the risk stratification of normotensive patients with pulmonary embolism: a prospective, cohort study with a three-month follow-up. Haematologica. 2005;90:423-424. (Pubitemid 40389004)
46. Post F, Mertens D, Sinning C, Peetz D, Münzel T. Decision for aggressive therapy in acute pulmonary embolism: implication of elevated troponin T. Clin Res Cardiol. 2009;98:401-408.
47. Konstantinides S, Geibel A, Olschewski M, Kasper W, Hruska N, Jäckle S, Binder L. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation. 2002;106: 1263-1268. (Pubitemid 34988646)
48. Douketis JD, Crowther MA, Stanton EB, Ginsberg JS. Elevated cardiac troponin levels in patients with submassive pulmonary embolism. Arch Intern Med. 2002;162:79-81. (Pubitemid 34073404)
49. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J. 2003;145:821-825. (Pubitemid 36570952)
50. La Vecchia L, Ottani F, Favero L, Spadaro GL, Rubboli A, Boanno C, Mezzena G, Fontanelli A, Jaffe AS. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart. 2004;90:633-637. (Pubitemid 38668535)
51. Douketis JD, Leeuwenkamp O, Grobara P, Johnston M, Söhne M, Ten Wolde M, Büller H. The incidence and prognostic significance of elevated cardiac troponins in patients with submassive pulmonary embolism. J Thromb Haemost. 2005;3:508-513. (Pubitemid 41632876)
52. Amorim S, Dias P, Rodrigues RA, Araújo V, Macedo F, Maciel MJ, Goncalves FR. Troponin I as a marker of right ventricular dysfunction and severity of pulmonary embolism. Rev Port Cardiol. 2006;25: 181-186.
53. Aksay E, Yanturali S, Kiyan S. Can elevated troponin I levels predict complicated clinical course and inhospital mortality in patients with acute pulmonary embolism? Am J Emerg Med. 2007;25:138-143. (Pubitemid 46185832)
54. Gallotta G, Palmieri V, Piedimonte V, Rendina D, De Bonis S, Russo V, Celentano A, Di Minno MN, Postiglione A, Di Minno G. Increased troponin I predicts in-hospital occurrence of hemodynamic instability in patients with sub-massive or non-massive pulmonary embolism independent to clinical, echocardiographic and laboratory information. Int J Cardiol. 2008;124:351-357. (Pubitemid 351305384)
55. Alonso Mart?́nez JL, Annicchérico Sánchez FJ, Urbieta Echezarreta MA, Garc?́a Sanchotena JL, Ezcurra Ibáñez M, Lasa Inchausti B. Clinical usefulness of troponin I in acute pulmonary embolism [in Spanish]. Med Clin (Barc). 2009;133:201-205.
56. Kostrubiec M, Pruszczyk P, Bochowicz A, Pacho R, Szulc M, Kaczynska A, Styczynski G, Kuch-Wocial A, Abramczyk P, Bartoszewicz Z, Berent H, Kuczynska K. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J. 2005;26:2166-2172. (Pubitemid 41408001)
57. Scridon T, Scridon C, Skali H, Alvarez A, Goldhaber SZ, Solomon SD. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol. 2005;96: 303-305. (Pubitemid 40978593)
58. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, Konstantinides S. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation. 2005;112:1573-1579. (Pubitemid 41324518)
59. Kline JA, Hernandez-Nino J, Rose GA, Norton HJ, Camargo CA Jr. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit Care Med. 2006;34:2773-2780. (Pubitemid 44610942)
60. Hsu JT, Chu CM, Chang ST, Cheng HW, Cheng NJ, Chung CM. Prognostic role of right ventricular dilatation and troponin I elevation in acute pulmonary embolism. Int Heart J. 2006;47:775-781. (Pubitemid 44768728)
61. Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartiere JM, Chavelas C, Bonnin F, Stievenart JL, Solal AC. Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. Intensive Care Med. 2007;33:286-292. (Pubitemid 46221234)
62. Maziere F, Birolleau S, Medimagh S, Arthaud M, Bennaceur M, Riou B, Ray P. Comparison of troponin I and N-terminal-pro B-type natriuretic peptide for risk stratification in patients with pulmonary embolism. Eur J Emerg Med. 2007;14:207-211. (Pubitemid 47051935)
63. Zhu L, Yang YH, Wu YF, Zhai ZG, Wang C; National Project of the Diagnosis and Treatment Strategies for Pulmonary Thromboembolism Investigators. Value of transthoracic echocardiography combined with cardiac troponin I in risk stratification in acute pulmonary thromboembolism. Chin Med J. 2007;120:17-21. (Pubitemid 46117578)
64. Tulevski II, ten Wolde M, van Veldhuisen DJ, Mulder JW, van der Wall EE, Büller HR, Mulder BJ. Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int J Cardiol. 2007;116:161-166. (Pubitemid 46241473)
65. Kline JA, Zeitouni R, Marchick MR, Hernandez-Nino J, Rose GA. Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. Am Heart J. 2008;156:308-314.
66. Palmieri V, Gallotta G, Rendina D, De Bonis S, Russo V, Postiglione A, Martino S, Di Minno MN, Celentano A. Troponin I and right ventricular dysfunction for risk assessment in patients with nonmassive pulmonary embolism in the Emergency Department in combination with clinically based risk score. Intern Emerg Med. 2008;3:131-138.
67. Toosi MS, Merlino JD, Leeper KV. Prognostic value of the shock index along with transthoracic echocardiography in risk stratification of patients with acute pulmonary embolism. Am J Cardiol. 2008;101: 700-705. (Pubitemid 351625098)
68. Jiménez D, D?́az G, Molina J, Mart?́ D, Del Rey J, Garc?́a-Rull S, Escobar C, Vidal R, Sueiro A, Yusen RD. Troponin I and risk stratification of patients with acute nonmassive pulmonary embolism. Eur Respir J. 2008;31:847-853.
69. Bova C, Pesavento R, Marchiori A, Palla A, Enea I, Pengo V, Visoná A, Noto A, Prandoni P; TELESIO Study Group. Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with 3 months of follow-up. J Thromb Haemost. 2009;7:938-944.
70. Vuilleumier N, Le Gal G, Verschuren F, Perrier A, Bounameaux H, Turck N, Sanchez JC, Mensi N, Perneger T, Hochstrasser D, Righini M. Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost. 2009; 7:391-398.
71. Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL, Monreal M; RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad Trombo- Embolica venosa (RIETE) Registry. Circulation. 2008;117:1711-1716. (Pubitemid 351482603)
72. Aujesky D, Perrier A, Roy PM, Stone RA, Cornuz J, Meyer G, Obrosky DS, Fine MJ. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med. 2007;261: 597-604. (Pubitemid 46835983)
73. Aujesky D, Roy PM, Le Manach CP, Verschuren F, Meyer G, Obrosky DS, Stone RA, Cornuz J, Fine MJ. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J. 2006;27:476-481. (Pubitemid 43209175)
74. Jardin F, Dubourg O, Guéret P, Delorme G, Bourdarias JP. Quantitative two-dimensional echocardiography in massive pulmonary embolism: emphasis on ventricular interdependence and leftward septal displacement. J Am Coll Cardiol. 1987;10:1201-1206. (Pubitemid 18004669)
75. Kjaergaard J, Schaadt BK, Lund JO, Hassager C. Quantitative measures of right ventricular dysfunction by echocardiography in the diagnosis of acute nonmassive pulmonary embolism. J Am Soc Echocardiogr. 2006; 19:1264-1271. (Pubitemid 44416170)
76. Kjaergaard J, Schaadt BK, Lund JO, Hassager C. Quantification of right ventricular function in acute pulmonary embolism: relation to extent of pulmonary perfusion defects. Eur J Echocardiogr. 2008;9:641-645.
77. Kjaergaard J, Sogaard P, Hassager C. Right ventricular strain in pulmonary embolism by Doppler tissue echocardiography. J Am Soc Echocardiogr. 2004;17:1210-1212. (Pubitemid 39388916)
78. Wolfe MW, Lee RT, Feldstein ML, Parker JA, Come PC, Goldhaber SZ. Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism. Am Heart J. 1994;127: 1371-1375. (Pubitemid 24176030)
79. Goldhaber SZ, Come PC, Lee RT, Braunwald E, Parker JA, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Mogtader A, McDonough TJ. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507-511. (Pubitemid 23066083)
80. Jerjes-Sanchez C, Ramirez-Rivera A, Arriaga-Nava R, Iglesias- Gonzalez S, Gutierrez P, Ibarra-Perez C, Martinez A, Valencia S, Rosado-Buzzo A, Pierzo JA, Rosas E. High dose and short-term streptokinase infusion in patients with pulmonary embolism: prospective with seven-year follow-up trial. J Thromb Thrombolysis. 2001;12: 237-247. (Pubitemid 34279445)
81. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart. 1997;77:346-349. (Pubitemid 27208175)
82. Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, Meyer G. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J. 2008;29:1569-1577. (Pubitemid 351881988)
83. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol. 2000;36:1632-1636.
84. Pacouret G, Schellenberg F, Hamel E, Charbonnier B, Mouray H. Troponin I in massive acute pulmonary embolism: results of a prospective series [in French]. Presse Med. 1998;27:1627. (Pubitemid 28494261)
85. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116: 427-433. (Pubitemid 47196548)
86. Tulevski II, Hirsch A, Sanson BJ, Romkes H, van der Wall EE, van Veldhuisen DJ, Büller HR, Mulder BJ. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost. 2001;86:1193-1196. (Pubitemid 33064567)
87. Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med. 2008; 34:2147-2156.
88. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178:425-430.
89. Ghanima W, Abdelnoor M, Holmen LO, Nielssen BE, Ross S, Sandset PM. D-dimer level is associated with the extent of pulmonary embolism. Thromb Res. 2007;120:281-288. (Pubitemid 46759553)
90. Kaczyñska A, Pelsers MM, Bochowicz A, Kostrubiec M, Glatz JF, Pruszczyk P. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta. 2006;371:117-123. (Pubitemid 44162903)
91. Puls M, Dellas C, Lankeit M, Olschewski M, Binder L, Geibel A, Reiner C, Schäfer K, Hasenfuss G, Konstantinides S. Heart-type fatty acidbinding protein permits early risk stratification of pulmonary embolism. Eur Heart J. 2007;28:224-229.
92. Dellas C, Puls M, Lankeit M, Schäfer K, Cuny M, Berner M, Hasenfuss G, Konstantinides S. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol. 2010;55: 2150-2157.
93. Abecasis J, Monge J, Alberca D, Grenho MF, Arroja I, Aleixo AM. Electrocardiographic presentation of massive and submassive pulmonary embolism. Rev Port Cardiol. 2008;27:591-610.
94. Ahonen A. Electrocardiographic changes in massive pulmonary embolism, II: analysis of the changes in ST segment and T wave. Acta Med Scand. 1977;201:543-545. (Pubitemid 8135448)
95. de Meester A, Deltenre P, Chaudron JM. Major prolongation of the QT interval observed in the course of massive pulmonary embolism [in French]. Acta Clin Belg. 1995;50:301-304.
96. Lin JF, Li YC, Yang PL. A case of massive pulmonary embolism with ST elevation in leads V1-4. Circ J. 2009;73:1157-1159.
97. Petrov DB. Appearance of right bundle branch block in electrocardiograms of patients with pulmonary embolism as a marker for obstruction of the main pulmonary trunk. J Electrocardiol. 2001;34:185-188.
98. Stein PD, Dalen JE, McIntyre KM, Sasahara AA, Wenger NK, Willis PW 3rd. The electrocardiogram in acute pulmonary embolism. Prog Cardiovasc Dis. 1975;17:247-257.
99. Yeh KH, Chang HC. Massive pulmonary embolism with anterolateral ST-segment elevation: electrocardiogram limitations and the role of echocardiogram. Am J Emerg Med. 2008;26:632.e1- 632.e3.
100. Yoshinaga T, Ikeda S, Shikuwa M, Miyahara Y, Kohno S. Relationship between ECG findings and pulmonary artery pressure in patients with acute massive pulmonary thromboembolism. Circ J. 2003;67:229-232. (Pubitemid 36362498)
101. Vanni S, Polidori G, Vergara R, Pepe G, Nazerian P, Moroni F, Garbelli E, Daviddi F, Grifoni S. Prognostic value of ECG among patients with acute pulmonary embolism and normal blood pressure. Am J Med. 2009;122:257-264.
102. Geibel A, Zehender M, Kasper W, Olschewski M, Klima C, Konstantinides SV. Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. Eur Respir J. 2005;25:843-848. (Pubitemid 40667682)
103. Ferrari E, Imbert A, Chevalier T, Mihoubi A, Morand P, Baudouy M. The ECG in pulmonary embolism: predictive value of negative T waves in precordial leads: 80 case reports. Chest. 1997;111:537-543. (Pubitemid 27132922)
104. Kanbay A, Kokturk N, Kaya MG, Tulmac M, Akbulut A, Ilhan MN, Unlu M, Ekim N. Electrocardiography and Wells scoring in predicting the anatomic severity of pulmonary embolism. Respir Med. 2007;101: 1171-1176. (Pubitemid 46667676)
105. Nielsen TT, Lund O, Rnne K, Schifter S. Changing electrocardiographic findings in pulmonary embolism in relation to vascular obstruction. Cardiology. 1989;76:274-284. (Pubitemid 19243857)
106. Toosi MS, Merlino JD, Leeper KV. Electrocardiographic score and short-term outcomes of acute pulmonary embolism. Am J Cardiol. 2007;100:1172-1176. (Pubitemid 47404476)
107. Escobar C, Jiménez D, Mart?́ D, Lobo JL, D?́az G, Gallego P, Vidal R, Barrios V, Sueiro A. Prognostic value of electrocardiographic findings in hemodynamically stable patients with acute symptomatic pulmonary embolism [in Spanish]. Rev Esp Cardiol. 2008;61:244-250. (Pubitemid 351928297)
108. Kosuge M, Kimura K, Ishikawa T, Ebina T, Hibi K, Tsukahara K, Kanna M, Iwahashi N, Okuda J, Nozawa N, Ozaki H, Yano H, Nakati T, Kusama I, Umemura S. Prognostic significance of inverted T waves in patients with acute pulmonary embolism. Circ J. 2006;70:750-755. (Pubitemid 43797787)
109. Kucher N, Walpoth N, Wustmann K, Noveanu M, Gertsch M. QR in V1: an ECG sign associated with right ventricular strain and adverse clinical outcome in pulmonary embolism. Eur Heart J. 2003;24:1113-1119. (Pubitemid 36723576)
110. Daniel KR, Courtney DM, Kline JA. Assessment of cardiac stress from massive pulmonary embolism with 12-lead ECG. Chest. 2001;120: 474-481. (Pubitemid 32881264)
111. Kucher N, Wallmann D, Carone A, Windecker S, Meier B, Hess OM. Incremental prognostic value of troponin I and echocardiography in patients with acute pulmonary embolism. Eur Heart J. 2003;24: 1651-1656. (Pubitemid 37174904)
112. Enea I, Ceparano G, Mazzarella G, Di Sarno R, Cangiano G, Busino CA. Biohumoral markers and right ventricular dysfunction in acute pulmonary embolism: the answer to thrombolytic therapy [in Italian]. Ital Heart J Suppl. 2004;5:29-35.
113. Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, Olschewski M, Konstantinides S, Wollert KC. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008;177:1018-1025. (Pubitemid 351717597)
114. Warkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(suppl):340S-380S. (Pubitemid 351892970)
115. Bell WR. Present-day thrombolytic therapy: therapeutic agents: pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002; 3(suppl 2):S34-S44. (Pubitemid 36221609)
116. Urokinase-streptokinase embolism trial: phase 2 results: a cooperative study. JAMA. 1974;229:1606-1613.
117. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, Nagel JS, Meyerovitz M, Kim D, Vaughan DE, Tumeh SS, Loscalzo J, Selwyn AP, Braunwald E. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2:293-298.
118. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002; 347:1143-1150.
119. Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, Berg G. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999;138(pt 1):39-44. (Pubitemid 29331118)
120. Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, Balsemin F, Campanini M, Ghirarduzzi A, Casazza F; TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010; 125:e82-e86.
121. US Food and Drug Administration. How drugs are developed and approved: therapeutic biologic applications (BLA). http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080871.pdf. Accessed March 1, 2010.
122. de Groot MR, Oostdijk AH, Engelage AH, van Marwijk Kooy M, Büller HR. Changes in perfusion scintigraphy in the first days of heparin therapy in patients with acute pulmonary embolism. Eur J Nucl Med. 2000;27:1481-1486.
123. Parker JA, Markis JE, Palla A, Goldhaber SZ, Royal HD, Tumeh S, Kim D, Rustgi AK, Holman BL, Kolodny GM. Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning. Radiology. 1988;166:441-445. (Pubitemid 18030755)
124. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G, Morpurgo M, Marini MG, Visani L. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. 1992;20: 520-526.
125. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol. 1997;80:184-188. (Pubitemid 27329218)
126. Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Holt JM, Thomas ML, Lee G, Miller GA, Sharp AA, Sutton GC. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J. 1974;1:343-347.
127. PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study by the PIOPED Investigators. Chest. 1990;97:528-533.
128. Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol. 1998;82:966-970. (Pubitemid 28480783)
129. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation. 1973;47(suppl):II-1-II-108.
130. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98:1473-1479.
131. Jerjes-Sanchez C, Ram?́rez-Rivera A, de Lourdes Garc?́a M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, Pierzo JA, Rosas E. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995; 2:227-229.
132. Dotter CT, Seamon AJ, Rösch J, Porter JM. Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison. Vasc Endovascular Surg. 1979;13:42-52. (Pubitemid 9170443)
133. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand. 1978;203:465-470. (Pubitemid 8358211)
134. Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration. 1988;54:162-173.
135. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
136. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a metaanalysis of the randomized controlled trials. Circulation. 2004;110: 744-749. (Pubitemid 39056276)
137. Thabut G, Thabut D, Myers RP, Bernard-Chabert B, Marrash-Chahla R, Mal H, Fournier M. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol. 2002;40:1660-1667. (Pubitemid 35253645)
138. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, Iversen S, Redecker M, Kienast J, Just H, Kasper W. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96:882-888. (Pubitemid 27329623)
139. Lobo JL, Zorrilla V, Aizpuru F, Uresandi F, Garcia-Bragado F, Conget F, Monreal M. Clinical syndromes and clinical outcome in patients with pulmonary embolism: findings from the RIETE registry. Chest. 2006; 130:1817-1822. (Pubitemid 46033439)
140. Schreiber D, Lin B, Liu G, Briese B, Hiestand B, Slatter D, Kline J, Pollack C. Variation in therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry (EMPEROR). Acad Emerg Med. 2009;16(S77).
141. HCUP Databases (Healthcare Cost and Utilization Project). Agency for Healthcare Research and Quality, Rockville, MD. Overview of the 2007 Nationwide Inpatient Sample (NIS). http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed March 1, 2010.
142. De Soyza ND, Murphy ML. Persistent post-embolic pulmonary hypertension. Chest. 1972;62:665-668.
143. Schwarz F, Stehr H, Zimmermann R, Manthey J, Kübler W. Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism. Circulation. 1985;71:117-123. (Pubitemid 15164770)
144. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vasc Med. 2000;5:91-95. (Pubitemid 30485303)
145. Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest. 2009;136:1202-1210.
146. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) [published corrections appear in Circulation. 2005;111:2013-2014, 2007:115:e411, and 2010;121:e441]. Circulation. 2004;110:e82-e292.
147. Otero R, Trujillo-Santos J, Cayuela A, Rodr?́guez C, Barron M, Mart?́n JJ, Monreal M; Registro Informatizado de la Enfermedad Tromboembo ́lica (RIETE) Investigators. Haemodynamically unstable pulmonary embolism in the RIETE Registry: systolic blood pressure or shock index? Eur Respir J. 2007;30:1111-1116. (Pubitemid 351194757)
148. Kline JA, Hernandez-Nino J, Newgard CD, Cowles DN, Jackson RE, Courtney DM. Use of pulse oximetry to predict in-hospital complications in normotensive patients with pulmonary embolism. Am J Med. 2003;115:203-208. (Pubitemid 37338145)
149. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-381. (Pubitemid 13215050)
150. Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, Marbet GA, Mombaerts P, Olsson CG. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation. 1988;77: 353-360. (Pubitemid 18060044)
151. Kucher N, Luder CM, Dörnhöfer T, Windecker S, Meier B, Hess OM. Novel management strategy for patients with suspected pulmonary embolism. Eur Heart J. 2003;24:366-376. (Pubitemid 36215970)
152. Böttiger BW, Arntz HR, Chamberlain DA, Bluhmki E, Belmans A, Danays T, Carli PA, Adgey JA, Bode C, Wenzel V; TROICA Trial Investigators; European Resuscitation Council Study Group. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008;359:2651-2662.
153. Kucher N. Catheter embolectomy for acute pulmonary embolism. Chest. 2007;132:657-663. (Pubitemid 47282401)
154. Greenfield LJ, Proctor MC, Williams DM, Wakefield TW. Long-term experience with transvenous catheter pulmonary embolectomy. J Vasc Surg. 1993;18:450-457.
155. Handa K, Sasaki Y, Kiyonaga A, Fujino M, Hiroki T, Arakawa K. Acute pulmonary thromboembolism treated successfully by balloon angioplasty: a case report. Angiology. 1988;39:775-778.
156. Schmitz-Rode T, Janssens U, Duda SH, Erley CM, Günther RW. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol. 2000;36:375-380. (Pubitemid 30623995)
157. Fava M, Loyola S. Applications of percutaneous mechanical thrombectomy in pulmonary embolism. Tech Vasc Interv Radiol. 2003;6: 53-58. (Pubitemid 36605508)
158. Cho KJ, Dasika NL. Catheter technique for pulmonary embolectomy or thrombofragmentation. Semin Vasc Surg. 2000;13:221-235.
159. Kucher N, Windecker S, Banz Y, Schmitz-Rode T, Mettler D, Meier B, Hess OM. Percutaneous catheter thrombectomy device for acute pulmonary embolism: in vitro and in vivo testing. Radiology. 2005;236: 852-858. (Pubitemid 41170847)
160. Skaf E, Beemath A, Siddiqui T, Janjua M, Patel NR, Stein PD. Catheter-tip embolectomy in the management of acute massive pulmonary embolism. Am J Cardiol. 2007;99:415-420. (Pubitemid 46149564)
161. Chechi T, Vecchio S, Spaziani G, Giuliani G, Giannotti F, Arcangeli C, Rubboli A, Margheri M. Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism. Catheter Cardiovasc Interv. 2009;73:506-513.
162. Biederer J, Charalambous N, Paulsen F, Heller M, Müller- Hülsbeck S. Treatment of acute pulmonary embolism: local effects of three hydrodynamic thrombectomy devices in an ex vivo porcine model. J Endovasc Ther. 2006;13:549-560. (Pubitemid 44423049)
163. Sukhija R, Aronow WS, Lee J, Kakar P, McClung JA, Levy JA, Belkin RN. Association of right ventricular dysfunction with in-hospital mortality in patients with acute pulmonary embolism and reduction in mortality in patients with right ventricular dysfunction by pulmonary embolectomy. Am J Cardiol. 2005;95:695-696. (Pubitemid 40255275)
164. Meneveau N, Séronde MF, Blonde MC, Legalery P, Didier-Petit K, Briand F, Caulfield F, Schiele F, Bernard Y, Bassand JP. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129:1043-1050.
165. Stein PD, Alnas M, Beemath A, Patel NR. Outcome of pulmonary embolectomy. Am J Cardiol. 2007;99:421-423. (Pubitemid 46149562)
166. Leacche M, Unic D, Goldhaber SZ, Rawn JD, Aranki SF, Couper GS, Mihaljevic T, Rizzo RJ, Cohn LH, Aklog L, Byrne JG. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005;129:1018-1023. (Pubitemid 40631421)
167. Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med. 2004;164:1541-1545. (Pubitemid 38970475)
168. Jaff MR, Goldhaber SZ, Tapson VF. High utilization rate of vena cava filters in deep vein thrombosis. Thromb Haemost. 2005;93:1117-1119. (Pubitemid 40823517)
169. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prévention du Risque dEmbolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409-415. (Pubitemid 28135667)
170. White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med. 2000;160:2033-2041. (Pubitemid 30437587)
171. Kinney TB. Update on inferior vena cava filters. J Vasc Interv Radiol. 2003;14:425-440. (Pubitemid 36423164)
172. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev. 2005;19:179-202. (Pubitemid 40387410)
173. Mohan CR, Hoballah JJ, Sharp WJ, Kresowik TF, Lu CT, Corson JD. Comparative efficacy and complications of vena caval filters. J Vasc Surg. 1995;21:235-245.
174. Ray CE Jr, Kaufman JA. Complications of inferior vena cava filters. Abdom Imaging. 1996;21:368-374. (Pubitemid 26230779)
175. Mewissen MW, Erickson SJ, Foley WD, Lipchik EO, Olson DL, McCann KM, Schreiber ER. Thrombosis at venous insertion sites after inferior vena caval filter placement. Radiology. 1989;173:155-157. (Pubitemid 19242424)
176. Chandra PA, Nwokolo C, Chuprun D, Chandra AB. Cardiac tamponade caused by fracture and migration of inferior vena cava filter. South Med J. 2008;101:1163-1164.
177. Konstantinides S, Geibel A, Kasper W, Olschewski M, Blümel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation. 1998;97: 1946-1951.
178. Kasper W, Geibel A, Tiede N, Just H. Patent foramen ovale in patients with haemodynamically significant pulmonary embolism. Lancet. 1992; 340:561-564.
179. Clergeau MR, Hamon M, Morello R, Saloux E, Viader F. Silent cerebral infarcts in patients with pulmonary embolism and a patent foramen ovale: a prospective diffusion-weighted MRI study. Stroke. 2009;40: 3758-3762.
180. Fauveau E, Cohen A, Bonnet N, Gacem K, Lardoux H. Surgical or medical treatment for thrombus straddling the patent foramen ovale: impending paradoxical embolism? Report of four clinical cases and literature review. Arch Cardiovasc Dis. 2008;101:637-644.
181. Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008;149:698-707.
182. Vedantham S, Grassi CJ, Ferral H, Patel NH, Thorpe PE, Antonacci VP, Janne Dothacuteee BM, Hofmann LV, Cardella JF, Kundu S, Lewis CA, Schwartzberg MS, Min RJ, Sacks D; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. J Vasc Interv Radiol. 2006;17:417-434.
183. Raju S, Fountain T, Neglén P, Devidas M. Axial transformation of the profunda femoris vein. J Vasc Surg. 1998;27:651-659. (Pubitemid 28201755)
184. Raju S, Fredericks R. Venous obstruction: an analysis of one hundred thirty-seven cases with hemodynamic, venographic, and clinical correlations. J Vasc Surg. 1991;14:305-313.
185. Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med. 2001;110:515-519.
186. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. Ann Surg. 2004;239:118-126. (Pubitemid 38176381)
187. Strandness DE Jr, Langlois Y, Cramer M, Randlett A, Thiele BL. Long-term sequelae of acute venous thrombosis. JAMA. 1983;250: 1289-1292. (Pubitemid 13049212)
188. ODonnell TF Jr, Browse NL, Burnand KG, Thomas ML. The socioeconomic effects of an iliofemoral venous thrombosis. J Surg Res. 1977;22:483-488. (Pubitemid 8106698)
189. Akesson H, Brudin L, Dahlström JA, Eklöf B, Ohlin P, Plate G. Venous function assessed during a 5 year period after acute ilio-femoral venous thrombosis treated with anticoagulation. Eur J Vasc Surg. 1990;4: 43-48. (Pubitemid 20133677)
190. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1:1309-1312.
191. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327: 1485-1489.
192. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119(suppl):108S-121S. (Pubitemid 32154197)
193. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med. 1996;156:1645-1649. (Pubitemid 26287120)
194. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized controlled trial. Ann Intern Med. 1993; 119:874-881. (Pubitemid 23316870)
195. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000;160: 181-188. (Pubitemid 30054337)
196. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Lowmolecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800-809. (Pubitemid 29231148)
197. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;(4):CD001100.
198. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
199. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators (Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety). Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 2001;344:626-631. (Pubitemid 32183577)
200. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001; 134:191-202.
201. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996;76:195-199. (Pubitemid 26285250)
202. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;72:186-190. (Pubitemid 24251277)
203. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867-873.
204. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism [published correction appears in N Engl J Med. 2004;350:423]. N Engl J Med. 2003;349:1695-1702.
205. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weightadjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006;296: 935-942. (Pubitemid 44285370)
206. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Lowmolecular- weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128:313-318. (Pubitemid 26087528)
207. Bauman ME, Belletrutti MJ, Bajzar L, Black KL, Kuhle S, Bauman ML, Massicotte MP. Evaluation of enoxaparin dosing requirements in infants and children: better dosing to achieve therapeutic levels. Thromb Haemost. 2009;101:86-92.
208. Nohe N, Flemmer A, Rümler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr. 1999; 158(suppl 3):S134-S139. (Pubitemid 30014020)
209. Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, Burrows P, Benson L, Williams W, David M, Poon A, Sparling K. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35:78-83. (Pubitemid 24004639)
210. Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, Morrow B, Gray L, ORourke K, Wells G, Kovacs J, Kovacs MJ. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2005;165:733-738. (Pubitemid 40569425)
211. Boccalon H, Elias A, Chalé JJ, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med. 2000;160:1769-1773. (Pubitemid 30418813)
212. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: the Tasman Study Group [published correction appears in N Engl J Med. 1997;337:1251]. N Engl J Med. 1996;334:682-687.
213. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecularweight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681. (Pubitemid 26079800)
214. Lubenow N, Eichler P, Lietz T, Greinacher A; HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005;3:2428-2436. (Pubitemid 41727158)
215. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparininduced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856. (Pubitemid 36960936)
216. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparininduced thrombocytopenia. Circulation. 2001;103:1838-1843. (Pubitemid 32328395)
217. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparininduced thrombocytopenia with thromboembolic complications: metaanalysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851. (Pubitemid 30616845)
218. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985;2:515-518. (Pubitemid 15236478)
219. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301: 855-858. (Pubitemid 10165871)
220. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
221. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: the Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336:393-398. (Pubitemid 27081901)
222. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639. (Pubitemid 36975995)
223. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434. (Pubitemid 36407171)
224. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome [published corrections appear in N Engl J Med. 2004;351:200 and 2003;349:2577]. N Engl J Med. 2003;349:1133-1138. (Pubitemid 37122325)
225. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, DAngelo A, Tognoni G, Barbui T. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-853. (Pubitemid 41632808)
226. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681. (Pubitemid 13206049)
227. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
228. Heit JA, Mohr DN, Silverstein MD, Petterson TM, OFallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768. (Pubitemid 30165236)
229. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
230. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-1665.
231. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M; SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004;2:743-749. (Pubitemid 40192487)
232. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis: a randomized study. Acta Med Scand. 1985;217:547-552. (Pubitemid 15019675)
233. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526. (Pubitemid 36976716)
234. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism [published correction appears in N Engl J Med. 1999;341:298]. N Engl J Med. 1999;340:901-907. (Pubitemid 29141050)
235. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy [published correction appears in N Engl J Med. 2006;355:2797]. N Engl J Med. 2006;355:1780-1789. (Pubitemid 44631361)
236. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001;345:165-169. (Pubitemid 32662124)
237. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349: 146-153.
238. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of lowmolecular- weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-1735.
239. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119: 1062-1072. (Pubitemid 44826932)
240. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, deVeber G, Leaker M, Chan AK, Massicotte MP. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr. 2000;136:439-445. (Pubitemid 30469583)
241. Sandoval JA, Sheehan MP, Stonerock CE, Shafique S, Rescorla FJ, Dalsing MC. Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk. J Vasc Surg. 2008;47:837-843.
242. Monagle P, Chalmers E, Chan A, DeVeber G, Kirkham F, Massicotte P, Michelson AD; American College of Chest Physicians. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(suppl):887S-968S. (Pubitemid 351892979)
243. Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, Tormene D, Mosena L, Pagnan A, Girolami A. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 2004;141:249-256.
244. Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997;349: 759-762. (Pubitemid 27122458)
245. Partsch H, Kaulich M, Mayer W. Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. Int Angiol. 2004;23: 206-212. (Pubitemid 40090113)
246. Ginsberg JS, Hirsh J, Julian J, Vander LaandeVries M, Magier D, MacKinnon B, Gent M. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med. 2001;161:2105-2109.
247. Ginsberg JS, Magier D, Mackinnon B, Gent M, Hirsh J. Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study. CMAJ. 1999;160:1303-1306. (Pubitemid 29225037)
248. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque dEmbolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112:416-422.
249. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003;1:1906-1913.
250. van der Heijden JF, Hutten BA, Büller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2002;(1):CD002001.
251. Kaufman JA, Rundback JH, Kee ST, Geerts W, Gillespie D, Kahn SR, Kearon C, Rectenwald J, Rogers FB, Stavropoulos SW, Streiff M, Vedantham S, Venbrux A. Development of a research agenda for inferior vena cava filters: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2009;20:697-707.
252. Cantwell CP, Pennypacker J, Singh H, Scorza LB, Waybill PN, Lynch FC. Comparison of the recovery and G2 filter as retrievable inferior vena cava filters. J Vasc Interv Radiol. 2009;20:1193-1199.
253. Saeed I, Garcia M, McNicholas K. Right ventricular migration of a recovery IVC filters fractured wire with subsequent pericardial tamponade. Cardiovasc Intervent Radiol. 2006;29:685-686. (Pubitemid 43823022)
254. Galhotra S, Amesur NB, Zajko AB, Simmons RL. Migration of the Günther Tulip inferior vena cava filter to the chest. J Vasc Interv Radiol. 2007;18:1581-1585. (Pubitemid 350151874)
255. Ziegler JW, Dietrich GJ, Cohen SA, Sterling K, Duncan J, Samotowka M. PROOF trial: protection from pulmonary embolism with the OptEase filter. J Vasc Interv Radiol. 2008;19:1165-1170.
256. Nazzal M, Chan E, Nazzal M, Abbas J, Erikson G, Sediqe S, Gohara S. Complications related to inferior vena cava filters: a single-center experience. Ann Vasc Surg. 2010;24:480-486.
257. Lyon SM, Riojas GE, Uberoi R, Patel J, Lipp ME, Plant GR, De Gregorio MA, Günther RW, Voorhees WD, McCann-Brown JA. Shortand long-term retrievability of the Celect vena cava filter: results from a multi-institutional registry. J Vasc Interv Radiol. 2009;20:1441-1448.
258. Van Ha TG, Chien AS, Funaki BS, Lorenz J, Piano G, Shen M, Leef J. Use of retrievable compared to permanent inferior vena cava filters: a single-institution experience. Cardiovasc Intervent Radiol. 2008;31: 308-315. (Pubitemid 351421904)
259. Raffini L, Cahill AM, Hellinger J, Manno C. A prospective observational study of IVC filters in pediatric patients. Pediatr Blood Cancer. 2008;51:517-520.
260. Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness DE Jr. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg. 1993;18:596-605.
261. OShaughnessy AM, Fitzgerald DE. The patterns and distribution of residual abnormalities between the individual proximal venous segments after an acute deep vein thrombosis. J Vasc Surg. 2001;33:379-384.
262. Prandoni P, Frulla M, Sartor D, Concolato A, Girolami A. Vein abnormalities and the post-thrombotic syndrome. J Thromb Haemost. 2005; 3:401-402.
263. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955-960. (Pubitemid 35440241)
264. Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med. 2005;118:456-464. (Pubitemid 40615466)
265. Elliot MS, Immelman EJ, Jeffery P, Benatar SR, Funston MR, Smith JA, Shepstone BJ, Ferguson AD, Jacobs P, Walker W, Louw JH. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg. 1979;66:838-843. (Pubitemid 10167777)
266. Arnesen H, Hiseth A, Ly B. Streptokinase of heparin in the treatment of deep vein thrombosis: follow-up results of a prospective study. Acta Med Scand. 1982;211:65-68. (Pubitemid 12184325)
267. Turpie AG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R, Gent M. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis: results of a randomized trial. Chest. 1990;97(suppl): 172S-175S. (Pubitemid 20119571)
268. Plate G, Einarsson E, Ohlin P, Jensen R, Qvarfordt P, Eklöf B. Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis. J Vasc Surg. 1984;1:867-876. (Pubitemid 15056084)
269. Plate G, Akesson H, Einarsson E, Ohlin P, Eklöf B. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. Eur J Vasc Surg. 1990;4:483-489. (Pubitemid 20347992)
270. Comerota AJ, Throm RC, Mathias SD, Haughton S, Mewissen M. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg. 2000;32:130-137. (Pubitemid 30461161)
271. AbuRahma AF, Perkins SE, Wulu JT, Ng HK. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg. 2001;233:752-760. (Pubitemid 32494555)
272. Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology. 1994;191: 487-494.
273. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry [published correction appears in Radiology. 1999;213:930]. Radiology. 1999;211:39-49. (Pubitemid 29161732)
274. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis: a randomised clinical trial. Eur J Vasc Endovasc Surg. 2002;24:209-214. (Pubitemid 41085793)
275. Enden T, Klw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM; CaVenT Study Group. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost. 2009;7:1268-1275.
276. Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med. 1984;76: 393-397. (Pubitemid 14159549)
277. Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, Sobel M, Wheeler HB, Plante D, Kim H, Hopkins A, Tufte M, Stump D. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med. 1990;88:235-240. (Pubitemid 20100369)
278. Shortell CK, Queiroz R, Johansson M, Waldman D, Illig KA, Ouriel K, Green RM. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion. J Vasc Surg. 2001;34:854-859. (Pubitemid 33661035)
279. Sugimoto K, Hofmann LV, Razavi MK, Kee ST, Sze DY, Dake MD, Semba CP. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg. 2003;37:512-517. (Pubitemid 36350891)
280. Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol. 2004;15:347-352. (Pubitemid 38451977)
281. Ouriel K, Katzen B, Mewissen M, Flick P, Clair DG, Benenati J, McNamara TO, Gibbens D. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol. 2000;11:849-854. (Pubitemid 30485096)
282. Castaneda F, Li R, Young K, Swischuk JL, Smouse B, Brady T. Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study. J Vasc Interv Radiol. 2002;13:577-580. (Pubitemid 34625716)
283. Razavi MK, Wong H, Kee ST, Sze DY, Semba CP, Dake MD. Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. J Endovasc Ther. 2002;9:593-598. (Pubitemid 35416816)
284. Parikh S, Motarjeme A, McNamara T, Raabe R, Hagspiel K, Benenati JF, Sterling K, Comerota A. Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. J Vasc Interv Radiol. 2008;19:521-528. (Pubitemid 351424912)
285. Patel NH, Plorde JJ, Meissner M. Catheter-directed thrombolysis in the treatment of phlegmasia cerulea dolens. Ann Vasc Surg. 1998;12: 471-475. (Pubitemid 28411257)
286. Robinson DL, Teitelbaum GP. Phlegmasia cerulea dolens: treatment by pulse-spray and infusion thrombolysis. AJR Am J Roentgenol. 1993;160: 1288-1290. (Pubitemid 23165553)
287. Vedantham S, Thorpe PE, Cardella JF, Grassi CJ, Patel NH, Ferral H, Hofmann LV, Janne dOthée BM, Antonaci VP, Brountzos EN, Brown DB, Martin LG, Matsumoto AH, Meranze SG, Miller DL, Millward SF, Min RJ, Neithamer CD Jr, Rajan DK, Rholl KS, Schwartzberg MS, Swan TL, Towbin RB, Wiechmann BN, Sacks D. Quality improvement guidelines for the treatment of lower extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2006;17:435- 447; quiz 448.
288. Kasirajan K, Gray B, Ouriel K. Percutaneous AngioJet thrombectomy in the management of extensive deep venous thrombosis. J Vasc Interv Radiol. 2001;12:179-185. (Pubitemid 32167779)
289. Vedantham S, Vesely TM, Parti N, Darcy M, Hovsepian DM, Picus D. Lower extremity venous thrombolysis with adjunctive mechanical thrombectomy. J Vasc Interv Radiol. 2002;13:1001-1008. (Pubitemid 35231856)
290. Delomez M, Beregi JP, Willoteaux S, Bauchart JJ, Janne dOthée B, Asseman P, Perez N, Théry C. Mechanical thrombectomy in patients with deep venous thrombosis. Cardiovasc Intervent Radiol. 2001;24: 42-48. (Pubitemid 32204952)
291. Vedantham S, Vesely TM, Sicard GA, Brown D, Rubin B, Sanchez LA, Parti N, Picus D. Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis. J Vasc Interv Radiol. 2004;15:565-574. (Pubitemid 38758441)
292. Kim HS, Patra A, Paxton BE, Khan J, Streiff MB. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. J Vasc Interv Radiol. 2006;17: 1099-1104. (Pubitemid 44318690)
293. Lin PH, Zhou W, Dardik A, Mussa F, Kougias P, Hedayati N, Naoum JJ, El Sayed H, Peden EK, Huynh TT. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptom-atic lower extremity deep venous thrombosis. Am J Surg. 2006;192: 782-788. (Pubitemid 44854822)
294. Arko FR, Davis CM 3rd, Murphy EH, Smith ST, Timaran CH, Modrall JG, Valentine RJ, Clagett GP. Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results. Arch Surg. 2007;142:513-518. (Pubitemid 46956393)
295. Cynamon J, Stein EG, Dym RJ, Jagust MB, Binkert CA, Baum RA. A new method for aggressive management of deep vein thrombosis: retrospective study of the power pulse technique. J Vasc Interv Radiol. 2006;17:1043-1049. (Pubitemid 44315483)
296. OSullivan GJ, Lohan DG, Gough N, Cronin CG, Kee ST. Pharmacomechanical thrombectomy of acute deep vein thrombosis with the Trellis-8 isolated thrombolysis catheter. J Vasc Interv Radiol. 2007;18: 715-724. (Pubitemid 46783618)
297. Hilleman DE, Razavi MK. Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombosis. J Vasc Interv Radiol. 2008;19:377-383. (Pubitemid 351273623)
298. Rao AS, Konig G, Leers SA, Cho J, Rhee RY, Makaroun MS, Chaer RA. Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis: an alternative in patients with contraindications to thrombolysis. J Vasc Surg. 2009;50:1092-1098.
299. Tsai J, Georgiades CS, Hong K, Kim HS. Presumed pulmonary embolism following power-pulse spray thrombectomy of upper extremity venous thrombosis. Cardiovasc Intervent Radiol. 2006;29: 678-680. (Pubitemid 43823020)
300. Kuhle S, Koloshuk B, Marzinotto V, Bauman M, Massicotte P, Andrew M, Chan A, Abdolell M, Mitchell L. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res. 2003;111:227-233. (Pubitemid 38021940)
301. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ; Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children [published correction appears in N Engl J Med. 2005;352:2146]. N Engl J Med. 2004;351:1081-1088.
302. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood. 2007;110:45-53. (Pubitemid 47026817)
303. Gupta AA, Leaker M, Andrew M, Massicotte P, Liu L, Benson LN, McCrindle BW. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr. 2001;139:682-688. (Pubitemid 33097434)
304. Bjarnason H, Kruse JR, Asinger DA, Nazarian GK, Dietz CA Jr, Caldwell MD, Key NS, Hirsch AT, Hunter DW. Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol. 1997;8: 405-418. (Pubitemid 27524134)
305. Ouriel K, Veith FJ, Sasahara AA; Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med. 1998;338:1105-1111. (Pubitemid 28227480)
306. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg. 1994;220:251-266.
307. Cockett FB, Thomas ML. The iliac compression syndrome. Br J Surg. 1965;52:816-821.
308. Lou WS, Gu JP, He X, Chen L, Su HB, Chen GP, Song JH, Wang T. Endovascular treatment for iliac vein compression syndrome: a comparison between the presence and absence of secondary thrombosis. Korean J Radiol. 2009;10:135-143.
309. Mickley V, Schwagierek R, Rilinger N, Görich J, Sunder-Plassmann L. Left iliac venous thrombosis caused by venous spur: treatment with thrombectomy and stent implantation. J Vasc Surg. 1998;28:492-497. (Pubitemid 28421721)
310. Hartung O, Benmiloud F, Barthelemy P, Dubuc M, Boufi M, Alimi YS. Late results of surgical venous thrombectomy with iliocaval stenting. J Vasc Surg. 2008;47:381-387. (Pubitemid 351172661)
311. Hartung O, Barthelemy P, Arnoux D, Boufi M, Alimi YS. Management of pregnancy in women with previous left ilio-caval stenting. J Vasc Surg. 2009;50:355-359.
312. Neglen P, Tackett TP Jr, Raju S. Venous stenting across the inguinal ligament. J Vasc Surg. 2008;48:1255-1261.
313. Raju S, Neglén P. Percutaneous recanalization of total occlusions of the iliac vein. J Vasc Surg. 2009;50:360-368.
314. Hartung O, Loundou AD, Barthelemy P, Arnoux D, Boufi M, Alimi YS. Endovascular management of chronic disabling ilio-caval obstructive lesions: long-term results. Eur J Vasc Endovasc Surg. 2009;38: 118-124.
315. Neglén P, Hollis KC, Raju S. Combined saphenous ablation and iliac stent placement for complex severe chronic venous disease. J Vasc Surg. 2006;44:828-833. (Pubitemid 44441786)
316. Fedullo PF, Rubin LJ, Kerr KM, Auger WR, Channick RN. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J. 2000;15:435-437. (Pubitemid 30158176)
317. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J. 2000;15:440-448. (Pubitemid 30158178)
318. Lang IM. Chronic thromboembolic pulmonary hypertension: not so rare after all. N Engl J Med. 2004;350:2236-2238. (Pubitemid 38669205)
319. Mo M, Kapelanski DP, Mitruka SN, Auger WR, Fedullo PF, Channick RN, Kerr K, Archibald C, Jamieson SW. Reoperative pulmonary thromboendarterectomy. Ann Thorac Surg. 1999;68:1770-1776.
320. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011-2020.
321. Hirsch AM, Moser KM, Auger WR, Channick RN, Fedullo PF. Unilateral pulmonary artery thrombotic occlusion: is distal arteriopathy a consequence? Am J Respir Crit Care Med. 1996;154(pt 1):491-496. (Pubitemid 26269124)
322. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation. 1999;99: 1325-1330. (Pubitemid 29129917)
323. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257-2264.
324. Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009;102:688-693.
325. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest. 2006;129:192-197. (Pubitemid 43265262)
326. Presti B, Berthrong M, Sherwin RM. Chronic thrombosis of major pulmonary arteries. Hum Pathol. 1990;21:601-606. (Pubitemid 20204947)
327. Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, Fedullo PF, Madani MM, Lin GY, Sakakibara N, Thistlethwaite PA, Jamieson SW, Rubin LJ, Yuan JX. Identification of putative endothelial progenitor cells (CD34-CD133-Flk-1-) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296:L870-L878.
328. Uchida Y, Oshima T, Hirose J, Sasaki T, Morizuki S, Morita T. Angioscopic detection of residual pulmonary thrombi in the differential diagnosis of pulmonary embolism. Am Heart J. 1995;130:854-859.
329. Dartevelle P, Fadel E, Chapelier A, Macchiarini P, Cerrina J, Parquin F, Simonneau F, Simonneau G. Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. Eur J Cardiothorac Surg. 1999;16:38-43. (Pubitemid 29336430)
330. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson SW, Thistlethwaite PA. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 2003;348:500-509. (Pubitemid 36159885)
331. Galiè N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3: 571-576. (Pubitemid 44411622)
332. Azarian R, Wartski M, Collignon MA, Parent F, Hervé P, Sors H, Simonneau G. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med. 1997;38:980-983. (Pubitemid 27251998)
333. Sacks RS, Remillard CV, Agange N, Auger WR, Thistlethwaite PA, Yuan JX. Molecular biology of chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg. 2006;18:265-276. (Pubitemid 44914579)
334. Thistlethwaite PA, Mo M, Madani MM, Deutsch R, Blanchard D, Kapelanski DP, Jamieson SW. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg. 2002;124:1203-1211. (Pubitemid 35417009)
335. Thistlethwaite PA, Madani M, Jamieson SW. Outcomes of pulmonary endarterectomy surgery. Semin Thorac Cardiovasc Surg. 2006;18: 257-264. (Pubitemid 44914583)
336. Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schönauer V, Exner M, Klepetko W, Kneussl MP, Maurer G, Lang I. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2005;93:512-516. (Pubitemid 40392541)
337. Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3:568-570. (Pubitemid 44411621)
338. Ja?̈s X, Ioos V, Jardim C, Sitbon O, Parent F, Hamid A, Fadel E, Dartevelle P, Simonneau G, Humbert M. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax. 2005;60:1031-1034. (Pubitemid 41705472)
339. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc. 2006;3:564-567. (Pubitemid 44411620)
340. Auger WR, Permpikul P, Moser KM. Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report. Am J Med. 1995;99:392-396.
341. Porres-Aguilar M, Pena-Ruiz MA, Burgos JD, Porres-Munoz M, Hughes HW. Chronic thromboembolic pulmonary hypertension as an uncommon presentation of primary antiphospholipid syndrome. J Natl Med Assoc. 2008;100:734-736. (Pubitemid 351874453)
342. Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin LJ, Kyrle PA, Klepetko W, Maurer G, Lang IM. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2003;90: 372-376. (Pubitemid 37138760)
343. Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G. Thrombotic risk factors in pulmonary hypertension. Eur Respir J. 2000;15:395-399. (Pubitemid 30085971)
344. Colorio CC, Martinuzzo ME, Forastiero RR, Pombo G, Adamczuk Y, Carreras LO. Thrombophilic factors in chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis. 2001;12:427-432. (Pubitemid 32803681)
345. Laczika K, Lang IM, Quehenberger P, Mannhalter C, Muhm M, Klepetko W, Kyrle PA. Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. Chest. 2002; 121:286-289. (Pubitemid 34114262)
346. Rubens FD, Sabloff M, Wells PS, Bourke M. Use of recombinanthirudin in pulmonary thromboendarterectomy. Ann Thorac Surg. 2000; 69:1942-1943.
347. Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL Jr. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med. 2006;173: 1270-1275. (Pubitemid 43848399)
348. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Nakanishi N. Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. Chest. 2003;124:1305-1311. (Pubitemid 37290039)
349. Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81:151-158. (Pubitemid 12165545)
350. Benotti JR, Ockene IS, Alpert JS, Dalen JE. The clinical profile of unresolved pulmonary embolism. Chest. 1983;84:669-678. (Pubitemid 14205444)
351. Parker BM, Smith JR. Pulmonary embolism and infarction: a review of the physiologic consequences of pulmonary arterial obstruction. Am J Med. 1958;24:402-427.
352. Auger WR, Fedullo PF. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med. 2009;30:471-483.
353. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT); Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263.
354. Hoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009;30:369-375.
355. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, Al-Nahhas A. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48:680-684. (Pubitemid 47604965)
356. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation. 2009;119:2250-2294.
357. Morris TA, Auger WR, Ysrael MZ, Olson LK, Channick RN, Fedullo PF, Moser KM. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest. 1996;110:399-403. (Pubitemid 26269268)
358. Fedullo PF, Kerr KM, Auger WR, Jamieson SW, Kapelanski DP. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med. 2000;21:563-574. (Pubitemid 32057644)
359. Blanchard DG, Malouf PJ, Gurudevan SV, Auger WR, Madani MM, Thistlethwaite P, Waltman TJ, Daniels LB, Raisinghani AB, DeMaria AN. Utility of right ventricular Tei index in the noninvasive evaluation of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy. JACC Cardiovasc Imaging. 2009; 2:143-149.
360. Menzel T, Wagner S, Kramm T, Mohr-Kahaly S, Mayer E, Braeuninger S, Meyer J. Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension: changes after pulmonary thromboendarterectomy. Chest. 2000;118:897-903.
361. Raisinghani A, Ben-Yehuda O. Echocardiography in chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg. 2006; 18:230-235. (Pubitemid 44914581)
362. Skoro-Sajer N, Becherer A, Klepetko W, Kneussl MP, Maurer G, Lang IM. Longitudinal analysis of perfusion lung scintigrams of patients with unoperated chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2004;92:201-207. (Pubitemid 39010884)
363. Ryan KL, Fedullo PF, Davis GB, Vasquez TE, Moser KM. Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension. Chest. 1988;93:1180-1185.
364. Auger WR, Kerr KM, Kim NH, Ben-Yehuda O, Knowlton KU, Fedullo PF. Chronic thromboembolic pulmonary hypertension. Cardiol Clin. 2004;22:453- 466, vii.
365. Skoro-Sajer N, Hack N, Sadushi-Kolici R, Bonderman D, Jakowitsch J, Klepetko W, Hoda MA, Kneussl MP, Fedullo P, Lang IM. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation. 2009;119: 298-305.
366. Thistlethwaite PA, Auger WR, Madani MM, Pradhan S, Kapelanski DP, Jamieson SW. Pulmonary thromboendarterectomy combined with other cardiac operations: indications, surgical approach, and outcome. Ann Thorac Surg. 2001;72:13-17.
367. Jamieson SW, Kapelanski DP. Pulmonary endarterectomy. Curr Probl Surg. 2000;37:165-252.
368. Coulden R. State-of-the-art imaging techniques in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3: 577-583. (Pubitemid 44411623)
369. Pitton MB, Düber C, Mayer E, Thelen M. Hemodynamic effects of nonionic contrast bolus injection and oxygen inhalation during pulmonary angiography in patients with chronic major-vessel thromboembolic pulmonary hypertension. Circulation. 1996;94:2485-2491. (Pubitemid 26403577)
370. Auger WR, Fedullo PF, Moser KM, Buchbinder M, Peterson KL. Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. Radiology. 1992;182:393-398.
371. Shure D, Gregoratos G, Moser KM. Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction. Ann Intern Med. 1985;103(pt 1):844-850. (Pubitemid 16175493)
372. Heinrich M, Uder M, Tscholl D, Grgic A, Kramann B, Schäfers HJ. CT scan findings in chronic thromboembolic pulmonary hypertension: predictors of hemodynamic improvement after pulmonary thromboendarterectomy. Chest. 2005;127:1606-1613. (Pubitemid 46218784)
373. Bergin CJ, Rios G, King MA, Belezzuoli E, Luna J, Auger WR. Accuracy of high-resolution CT in identifying chronic pulmonary thromboembolic disease. AJR Am J Roentgenol. 1996;166:1371-1377. (Pubitemid 26160592)
374. Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital subtraction angiography. Eur J Radiol. 2009;71:49-54.
375. Suga K, Kawakami Y, Iwanaga H, Hayashi N, Seto A, Matsunaga N. Comprehensive assessment of lung CT attenuation alteration at perfusion defects of acute pulmonary thromboembolism with breath-hold SPECT-CT fusion images. J Comput Assist Tomogr. 2006;30:83-91. (Pubitemid 43052304)
376. Kreitner KF, Ley S, Kauczor HU, Mayer E, Kramm T, Pitton MB, Krummenauer F, Thelen M. Chronic thromboembolic pulmonary hypertension: pre- and postoperative assessment with breath-hold MR imaging techniques. Radiology. 2004;232:535-543. (Pubitemid 38971297)
377. Reesink HJ, Marcus JT, Tulevski II, Jamieson S, Kloek JJ, Vonk Noordegraaf A, Bresser P. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to dem-onstrate restoration of the right ventricle. J Thorac Cardiovasc Surg. 2007;133:58-64. (Pubitemid 46014247)
378. Kovacs G, Reiter G, Reiter U, Rienmüller R, Peacock A, Olschewski H. The emerging role of magnetic resonance imaging in the diagnosis and management of pulmonary hypertension. Respiration. 2008;76: 458-470.
379. Cummings KW, Bhalla S. Multidetector computed tomographic pulmonary angiography: beyond acute pulmonary embolism. Radiol Clin North Am. 2010;48:51-65.
380. Madani MM, Jamieson SW. Technical advances of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg. 2006;18:243-249. (Pubitemid 44914578)
381. Couturaud F, Frachon I, Leroyer C. Chronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomy. Eur Respir J. 2009;33:230-232.
382. Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg. 2008;14:274-282.
383. Puis L, Vandezande E, Vercaemst L, Janssens P, Taverniers Y, Foulon M, Demeyere R, Delcroix M, Daenen W. Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Perfusion. 2005;20:101-108. (Pubitemid 40691879)
384. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg. 2005;28:882-888. (Pubitemid 41735269)
385. DArmini AM, Zanotti G, Viganò M. Pulmonary endarterectomy: the treatment of choice for chronic thromboembolic pulmonary hypertension. Ital Heart J. 2005;6:861-868.
386. Tanabe N, Amano S, Tatsumi K, Kominami S, Igarashi N, Shimura R, Matsubara H, Kasahara Y, Takiguchi Y, Kuriyama T. Angiotensinconverting enzyme gene polymorphisms and prognosis in chronic thromboembolic pulmonary hypertension. Circ J. 2006;70:1174-1179. (Pubitemid 44387000)
387. Reesink HJ, Meijer RC, Lutter R, Boomsma F, Jansen HM, Kloek JJ, Bresser P. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J. 2006;70: 1058-1063. (Pubitemid 44161746)
388. Piovella F, DArmini AM, Barone M, Tapson VF. Chronic thromboembolic pulmonary hypertension. Semin Thromb Hemost. 2006;32: 848-855. (Pubitemid 44956981)
389. Ogino H, Ando M, Matsuda H, Minatoya K, Sasaki H, Nakanishi N, Kyotani S, Imanaka H, Kitamura S. Japanese single-center experience of surgery for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 2006;82:630-636. (Pubitemid 44080057)
390. Mellemkjaer S, Ilkjaer LB, Klaaborg KE, Christiansen CL, Severinsen IK, Nielsen-Kudsk JE, Allermand H, Egeblad M, Kristensen BO. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: ten years experience in Denmark. Scand Cardiovasc J. 2006; 40:49-53. (Pubitemid 43203350)
391. Matsuda H, Ogino H, Minatoya K, Sasaki H, Nakanishi N, Kyotani S, Kobayashi J, Yagihara T, Kitamura S. Long-term recovery of exercise ability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 2006;82:1338-1343. (Pubitemid 44429915)
392. Macchiarini P, Kamiya H, Hagl C, Winterhalter M, Barbera J, Karck M, Pomar J, Haverich A. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: is deep hypothermia required? Eur J Cardiothorac Surg. 2006;30:237-241. (Pubitemid 44051921)
393. Lindner J, Jansa P, Kunstyr J, Mayer E, Blaha J, Palecek T, Aschermann M, Grus T, Ambroz D, Tosovský J, Vitkova I. Implementation of a new programme for the surgical treatment of CTEPH in the Czech Republic: pulmonary endarterectomy. Thorac Cardiovasc Surg. 2006;54: 528-531. (Pubitemid 46586281)
394. Ji B, Liu J, Wu Y, Wang G, Feng Z, Liu M, Long C, Song Y. Perfusion techniques for pulmonary thromboendarterectomy under deep hypothermia circulatory arrest: a case series. J Extra Corpor Technol. 2006; 38:302-306. (Pubitemid 351506743)
395. Suntharalingam J, Goldsmith K, Toshner M, Doughty N, Sheares KK, Hughes R, Jenkins D, Pepke-Zaba J. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir Med. 2007; 101:2254-2262. (Pubitemid 47484789)
396. Rubens FD, Bourke M, Hynes M, Nicholson D, Kotrec M, Boodhwani M, Ruel M, Dennie CJ, Mesana T. Surgery for chronic thromboembolic pulmonary hypertension: inclusive experience from a national referral center. Ann Thorac Surg. 2007;83:1075-1081. (Pubitemid 46328819)
397. Reesink HJ, van der Plas MN, Verhey NE, van Steenwijk RP, Kloek JJ, Bresser P. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2007;133:510-516. (Pubitemid 46136286)
398. Maeba H, Nakatani S, Sugawara M, Mimura J, Nakanishi N, Ogino H, Kitakaze M, Iwasaka T, Miyatake K. Different time course of changes in tricuspid regurgitant pressure gradient and pulmonary artery flow acceleration after pulmonary thromboendarterectomy: implications for discordant recovery of pulmonary artery pressure and compliance. Circ J. 2007;71:1771-1775. (Pubitemid 350240101)
399. Hardziyenka M, Reesink HJ, Bouma BJ, de Bruin-Bon HA, Campian ME, Tanck MW, van den Brink RB, Kloek JJ, Tan HL, Bresser P. A novel echocardiographic predictor of in-hospital mortality and mid-term haemodynamic improvement after pulmonary endarterectomy for chronic thrombo-embolic pulmonary hypertension. Eur Heart J. 2007; 28:842-849. (Pubitemid 47343590)
400. DArmini AM, Zanotti G, Ghio S, Magrini G, Pozzi M, Scelsi L, Meloni G, Klersy C, Viganò M. Reverse right ventricular remodeling after pulmonary endarterectomy. J Thorac Cardiovasc Surg. 2007;133: 162-168. (Pubitemid 46014213)
401. Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S, Klepetko W, Kneussl M, Lang IM. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation. 2007; 115:2153-2158. (Pubitemid 46659067)
402. Yoshimi S, Tanabe N, Masuda M, Sakao S, Uruma T, Shimizu H, Kasahara Y, Takiguchi Y, Tatsumi K, Nakajima N, Kuriyama T. Survival and quality of life for patients with peripheral type chronic thromboembolic pulmonary hypertension. Circ J. 2008;72:958-965. (Pubitemid 351879918)
403. Thomson B, Tsui SS, Dunning J, Goodwin A, Vuylsteke A, Latimer R, Pepke-Zaba J, Jenkins DP. Pulmonary endarterectomy is possible and effective without the use of complete circulatory arrest: the UK experience in over 150 patients. Eur J Cardiothorac Surg. 2008;33:157-163.
404. Mikus PM, Mikus E, Mart?́n-Suárez S, Galié N, Manes A, Pastore S, Arpesella G. Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results. Eur J Cardiothorac Surg. 2008;34:159-163.
405. Freed DH, Thomson BM, Tsui SS, Dunning JJ, Sheares KK, Pepke-Zaba J, Jenkins DP. Functional and haemodynamic outcome 1 year after pulmonary thromboendarterectomy. Eur J Cardiothorac Surg. 2008;34:525-529.
406. Corsico AG, DArmini AM, Cerveri I, Klersy C, Ansaldo E, Niniano R, Gatto E, Monterosso C, Morsolini M, Nicolardi S, Tramontin C, Pozzi E, Viganò M. Long-term outcome after pulmonary endarterectomy. Am J Respir Crit Care Med. 2008;178:419-424.
407. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, Tsui SS, Armstrong IJ, Torpy C, Crackett R, Carlin CM, Das C, Coghlan JG, Pepke-Zaba J. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008; 177:1122-1127. (Pubitemid 351717571)
408. von Haehling S, von Bardeleben RS, Kramm T, Thiermann Y, Niethammer M, Doehner W, Anker SD, Munzel T, Mayer E, Genth-Zotz S. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol. 2010;144:206-211.
409. Shigeta A, Tanabe N, Shimizu H, Hoshino S, Maruoka M, Sakao S, Tada Y, Kasahara Y, Takiguchi Y, Tatsumi K, Masuda M, Kuriyama T. Gender differences in chronic thromboembolic pulmonary hypertension in Japan. Circ J. 2008;72:2069-2074.
410. Saouti N, Morshuis WJ, Heijmen RH, Snijder RJ. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience. Eur J Cardiothorac Surg. 2009;35:947-952.
411. Lindner J, Maruna P, Kunstyr J, Jansa P, Gürlich R, Kubzova K, Zakharchenko M, Linhart A. Hemodynamic instability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension correlates with cytokine network hyperstimulation. Eur Surg Res. 2009; 43:39-46.
412. Ishida K, Masuda M, Tanaka H, Imamaki M, Katsumata M, Maruyama T, Miyazaki M. Mid-term results of surgery for chronic thromboembolic pulmonary hypertension. Interact Cardiovasc Thorac Surg. 2009;9: 626-629.
413. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Goldsmith K, Coghlan JG, Pepke-Zaba J. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:332-338.
414. Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:325-331.
415. van der Plas MN, Reesink HJ, Roos CM, van Steenwijk RP, Kloek JJ, Bresser P. Pulmonary endarterectomy improves dyspnea by the relief of dead space ventilation. Ann Thorac Surg. 2010;89:347-352.
416. Narayana Iyengar RM, Hegde D, Chattuparambil B, Gupta R, Patil L. Postoperative management of pulmonary endarterectomy and outcome. Ann Card Anaesth. 2010;13:22-27.
417. Mookadam F, Mookadam M, Jiamsripong P, Goel R. Pulmonary thromboembolic disease spectrum: diagnostic and therapeutic strategies. Expert Rev Cardiovasc Ther. 2009;7:1421-1428.
418. Dittrich HC, Nicod PH, Chow LC, Chappuis FP, Moser KM, Peterson KL. Early changes of right heart geometry after pulmonary thromboendarterectomy. J Am Coll Cardiol. 1988;11:937-943.
419. Sadeghi HM, Kimura BJ, Raisinghani A, Blanchard DG, Mahmud E, Fedullo PF, Jamieson SW, DeMaria AN. Does lowering pulmonary arterial pressure eliminate severe functional tricuspid regurgitation? Insights from pulmonary thromboendarterectomy. J Am Coll Cardiol. 2004;44:126-132. (Pubitemid 38968470)
420. Gurudevan SV, Malouf PJ, Kahn AM, Auger WR, Waltman TJ, Madani M, Demaria AN, Blanchard DG. Noninvasive assessment of pulmonary vascular resistance using Doppler tissue imaging of the tricuspid annulus. J Am Soc Echocardiogr. 2007;20:1167-1171. (Pubitemid 47484163)
421. Jamieson SW, Madani M. Invited commentary. Ann Thorac Surg. 2008; 86:1267.
422. Manecke GR Jr, Wilson WC, Auger WR, Jamieson SW. Chronic thromboembolic pulmonary hypertension and pulmonary thromboendarterectomy. Semin Cardiothorac Vasc Anesth. 2005;9:189-204. (Pubitemid 41285948)
423. Thistlethwaite PA, Madani M, Jamieson SW. Pulmonary thromboendarterectomy surgery. Cardiol Clin. 2004;22:467- 478, vii.
424. Thistlethwaite PA, Jamieson SW. Tricuspid valvular disease in the patient with chronic pulmonary thromboembolic disease. Curr Opin Cardiol. 2003;18:111-116.
425. Nagaya N, Ando M, Oya H, Ohkita Y, Kyotani S, Sakamaki F, Nakanishi N. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg. 2002;74:180-184. (Pubitemid 34742002)
426. Reesink HJ, Tulevski II, Marcus JT, Boomsma F, Kloek JJ, Vonk Noordegraaf A, Bresser P. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 2007;84: 537-543. (Pubitemid 47069203)
427. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006;98:525-529. (Pubitemid 44162883)
428. Dentali F, Donadini M, Gianni M, Bertolini A, Lonn E, Venco A, Cattozzo G, Ageno W. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med. 2009;4:123-128.
429. Lankeit M, Dellas C, Panzenböck A, Skoro-Sajer N, Bonderman D, Olschewski M, Schäfer K, Puls M, Konstantinides S, Lang IM. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2008;31: 1024-1029.
430. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:1211-1218.
431. Miller WT Jr, Osiason AW, Langlotz CP, Palevsky HI. Reperfusion edema after thromboendarterectomy: radiographic patterns of disease. J Thorac Imaging. 1998;13:178-183. (Pubitemid 28339873)
432. Thistlethwaite PA, Madani MM, Kemp AD, Hartley M, Auger WR, Jamieson SW. Venovenous extracorporeal life support after pulmonary endarterectomy: indications, techniques, and outcomes. Ann Thorac Surg. 2006;82:2139-2145.
433. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003;76:1457-1462.
434. Manecke GR Jr, Kotzur A, Atkins G, Fedullo PF, Auger WR, Kapelanski DP, Jamieson SW. Massive pulmonary hemorrhage after pulmonary thromboendarterectomy. Anesth Analg. 2004;99:672-675. (Pubitemid 39100350)
435. Archibald CJ, Auger WR, Fedullo PF, Channick RN, Kerr KM, Jamieson SW, Kapelanski DP, Watt CN, Moser KM. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 1999;160:523-528. (Pubitemid 29380667)
436. Mayer E, Dahm M, Hake U, Schmid FX, Pitton M, Kupferwasser I, Iversen S, Oelert H. Mid-term results of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 1996;61:1788-1792. (Pubitemid 26179731)
437. Tanabe N, Okada O, Nakagawa Y, Masuda M, Kato K, Nakajima N, Kuriyama T. The efficacy of pulmonary thromboendarterectomy on long-term gas exchange. Eur Respir J. 1997;10:2066-2072. (Pubitemid 27406443)
438. Zoia MC, DArmini AM, Beccaria M, Corsico A, Fulgoni P, Klersy C, Piovella F, Viganò M, Cerveri I; Pavia Thromboendarterectomy Group. Mid term effects of pulmonary thromboendarterectomy on clinical and cardiopulmonary function status. Thorax. 2002;57:608-612. (Pubitemid 34761763)
439. Scientific Registry of Transplant Recipients. http://www.ustransplant. org. Accessed March 1, 2010.
440. Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl):S85-S96.
441. Rubin LJ, Hoeper MM, Klepetko W, Galiè N, Lang IM, Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc. 2006;3:601-607. (Pubitemid 44411627)
442. Thistlethwaite PA, Kemp A, Du L, Madani MM, Jamieson SW. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2006; 131:307-313. (Pubitemid 43121551)
443. Kim NH. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3:584-588. (Pubitemid 44411624)
444. Dartevelle P, Fadel E, Mussot S, Chapelier A, Hervé P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, Sitbon O, Simonneau G. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23:637-648. (Pubitemid 38456010)
445. Kerr KM, Rubin LJ. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest. 2003;123:319-320. (Pubitemid 36269404)
446. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, Nakanishi N. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest. 2003;123:338-343. (Pubitemid 36269413)
447. Jensen KW, Kerr KM, Fedullo PF, Kim NH, Test VJ, Ben-Yehuda O, Auger WR. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009;120:1248-1254.
448. Jaïs X, DArmini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:2127-2134.
449. Seyfarth HJ, Hammerschmidt S, Pankau H, Winkler J, Wirtz H. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration. 2007;74:287-292. (Pubitemid 46828137)
450. Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, Huber L, Treder U, Fischler M. Bosentan therapy for chronic thromboembolic pulmonary hypertension: a national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly. 2007; 137:573-580.
451. Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, Simonneau G, Pepke-Zaba J. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006;28:138-143. (Pubitemid 44914271)
452. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, Lang IM. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2599-2603. (Pubitemid 41507615)
453. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schäfers HJ, Welte T, Mayer E. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2363-2367. (Pubitemid 41507580)
454. Hughes R, George P, Parameshwar J, Cafferty F, Dunning J, Morrell NW, Pepke-Zaba J. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax. 2005;60:707. (Pubitemid 41129077)
455. Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest. 2008;134:229-236.
456. Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2007;30:922-927. (Pubitemid 351194796)
457. Sheth A, Park JE, Ong YE, Ho TB, Madden BP. Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul Pharmacol. 2005;42:41-45. (Pubitemid 40259714)
458. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003;167:1139-1141. (Pubitemid 36459662)
459. Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2007;26:357-362. (Pubitemid 46522504)
460. Bresser P, Pepke-Zaba J, Ja?̈s X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc. 2006;3:594-600. (Pubitemid 44411626)
461. Scelsi L, Ghio S, Campana C, DArmini AM, Serio A, Klersy C, Piovella F, Viganò M, Tavazzi L. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. Ital Heart J. 2004; 5:618-623.
462. Skoro-Sajer N, Bonderman D, Wiesbauer F, Harja E, Jakowitsch J, Klepetko W, Kneussl MP, Lang IM. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2007;5:483-489. (Pubitemid 46680679)
463. Gomes WJ, Imaeda CJ, Perfeito JA, Sarmento PA, Souza RC, Forte V. Repeat pulmonary thromboendarterectomy after recurrence of chronic thromboembolic pulmonary hypertension. J Bras Pneumol. 2009;35: 91-94.
464. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines [published correction appears in JAMA. 2009;301:1544]. JAMA. 2009;301:831-841.